Form 4: Agilon Health CEO Steven Sell Reports Stock and Options Transactions
SEC Form 4 Filing
CEO Steven Sell reports acquisition and disposal of Agilon Health stock and options, including restricted stock units and options vesting over three years.
Summary
- Steven Sell, CEO and President of Agilon Health, filed a Form 4 detailing changes in beneficial ownership.
- On April 1, 2025, Sell acquired 551,471 shares of common stock at $0 and disposed of 906,781 shares.
- Following these transactions, Sell directly owns 906,781 shares of common stock and indirectly owns 67,590 shares through a trust.
- Sell also acquired 865,385 options with an exercise price of $4.08, vesting in three equal installments starting April 1, 2025, and expiring on April 1, 2035.
- The acquired common stock includes restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock and option transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The reported transactions reflect ongoing compensation and equity incentives for the CEO, with vesting schedules tied to continued employment.
Industry Context
Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company executives and directors.
Comparison to Industry Standards
- Equity compensation, including stock options and restricted stock units, is a common practice among publicly traded companies to align management's interests with those of shareholders.
- Vesting schedules, such as the three-year vesting period described in the filing, are typical for these types of equity grants.
- Comparing the size and terms of these grants to those of peer companies would provide further context on the competitiveness of Agilon Health's executive compensation practices.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and ownership.
- The vesting schedules incentivize the CEO to remain with the company and drive long-term value.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction, acquisition and disposal of shares and options, and vesting start date for restricted stock units and options. |
| 04/03/2025 | Date of signature for the Form 4 filing. |
| 04/01/2035 | Expiration date for the acquired options. |
Keywords
Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Agilon Health, AGL, Steven Sell, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.